Edward M. Gillis net worth and biography

Edward Gillis Biography and Net Worth

SVP of BioCardia

Ed Gillis joined BioCardia in 2020. Prior to joining us, Ed served as Chief Technical Officer and as President and Chief Executive Officer of ReVENT Medical, Inc., a company he founded. Prior to that he served as Vice President of Research and Development for SineXus (now Intersect ENT) and Apneon, an obstructive sleep apnea company. Ed was VP of Manufacturing and Engineering for Durect Corporation a pharmaceutical company developing drug delivery systems, catheters, and other delivery platforms. Previously, Ed worked in senior positions in manufacturing and product development for EndoTex Interventional Systems and Cardiac Pathways Corporation (both acquired by Boston Scientific) and engineering positions at Spectranetics Corporation, Guidant Corporation and Baxter Healthcare. He has built from scratch and provided leadership for early stage companies as well as R&D and manufacturing organizations. Ed received his Bachelor of Science in Biology and Master of Science in Plastics Engineering from The University of Massachusetts Lowell. He holds 34 US patents with 100+ issued and pending worldwide and is named author on scientific publications in the areas of obstructive sleep apnea, catheter design and drug delivery.

What is Edward M. Gillis' net worth?: The estimated net worth of Edward M. Gillis is at least $9.33 thousand as of December 20th, 2024. Mr. Gillis owns 8,968 shares of BioCardia stock worth more than $9,327 as of October 5th. This net worth estimate does not reflect any other investments that Mr. Gillis may own. Learn More about Edward M. Gillis' net worth.
How do I contact Edward M. Gillis?: The corporate mailing address for Mr. Gillis and other BioCardia executives is 320 Soquel Way, Sunnyvale, CA, 94085. BioCardia can also be reached via phone at (650) 226-0123 and via email at [email protected]. Learn More on Edward M. Gillis' contact information.
Has Edward M. Gillis been buying or selling shares of BioCardia?: Edward M. Gillis has not been actively trading shares of BioCardia in the last ninety days. Most recently, Edward M. Gillis sold 3,257 shares of the business's stock in a transaction on Friday, December 20th. The shares were sold at an average price of $2.00, for a transaction totalling $6,514.00. Following the completion of the sale, the senior vice president now directly owns 8,968 shares of the company's stock, valued at $17,936. Learn More on Edward M. Gillis' trading history.
Who are BioCardia's active insiders?: BioCardia's insider roster includes Peter Altman (CEO), Edward Gillis (SVP), and David Mcclung (CFO). Learn More on BioCardia's active insiders.
Are insiders buying or selling shares of BioCardia?: In the last twelve months, BioCardia insiders bought shares 26 times. They purchased a total of 169,900 shares worth more than $162,947.00. The most recent insider tranaction occured on September, 29th when CEO Peter Altman bought 1,000 shares worth more than $1,030.00. Insiders at BioCardia own 17.4% of the company. Learn More about insider trades at BioCardia.
Information on this page was last updated on 9/29/2026.

Edward M. Gillis Insider Trading History at BioCardia

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/20/2024	Sell	3,257	$2.00	$6,514.00	8,968

Edward M. Gillis Buying and Selling Activity at BioCardia

BioCardia Company Overview

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.

Today's Range

Now: $1.04

$1.03

$1.05

50 Day Range

MA: $1.02

$0.77

$1.25

2 Week Range

Now: $1.04

$0.75

$1.80

Volume

52,537 shs

Average Volume

360,126 shs

Market Capitalization

$15.75 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.62